First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients:

Seung Tae Kim,Jung Yong Hong,Se Hoon Park,Joon Oh Park,Young-Whan Park,N. Park,Hukeun Lee,Sung-Hee Hong,Song-Jae Lee,Seong-Won Song,Kyung Kim,Young Suk Park,Ho Yeong Lim,Won Ki Kang,Do-Hyun Nam,Jeong-Won Lee,Keunchil Park,Kyoung-Mee Kim,Jeeyun Lee

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients:

2020

Seung Tae Kim
Jung Yong Hong
Se Hoon Park
Joon Oh Park
Young-Whan Park
N. Park
Hukeun Lee
Sung-Hee Hong
Song-Jae Lee
Seong-Won Song
Kyung Kim
Young Suk Park
Ho Yeong Lim
Won Ki Kang
Do-Hyun Nam
Jeong-Won Lee
Keunchil Park
Kyoung-Mee Kim
Jeeyun Lee

Background:YYB101, a humanized monoclonal antibody against hepatocyte growth factor (HGF), has shown safety and efficacy in vitro and in vivo. This is a first-in-human trial of this antibody.Materi...

Keywords:

Monoclonal antibody
Pharmacodynamics
Pharmacology
Antibody
In vitro
In vivo
Hepatocyte growth factor
Refractory
Medicine
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations